Bortezomib CAS 179324-69-7 Ubunyulu ≥99.0% (HPLC) API Factory High Purity
Ukubonelela nge-Bortezomib eNxulumene ne-Intermediates kunye ne-High Purity
(1S,2S,3R,5S)-(+)-2,3-Pinanediol CAS 18680-27-8
(1R,2R,3S,5R)-(-)-2,3-Pinanediol CAS 22422-34-0
I-Bortezomib CAS 179324-69-7
| Igama leMchiza | Bortezomib |
| Izithethantonye | I-Velcade, i-MG-341, i-PS-341 |
| Inombolo yeCAS | 179324-69-7 |
| Inombolo yeCAT | RF-API65 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yeMveliso ukuya kumakhulu eeKilogram |
| Ifomula yeemolekyuli | I-C19H25BN4O4 |
| Ubunzima beMolekyuli | 384.24 |
| Indawo yokunyibilika | 122.0 ~ 124.0℃ |
| Ukuxinana | 1.214 |
| Refractive Index | 1.564 |
| Ukunyibilika | Inyibilika kwiChloroform, DMSO, Ethanol kunye neMethanol |
| Uzinzo | I-Hygroscopic kunye ne-Sensitive yokufuma |
| Imeko yokuthumela ngenqanawa | Ithunyelwe Ngaphantsi Kweqondo Lobushushu Le-Ambient |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Umgubo oMhlophe okanye oMhlophe |
| Ubunyulu / Indlela yokuHlalutya | ≥99.0% (HPLC) |
| Ilahleko ekomisweni | ≤0.50% |
| Intsalela kwi-Ignition | ≤0.20% |
| Ukujikeleziswa kwe-Optical | -41.0 ° ~ -46.0 ° |
| Intsimbi enzima | ≤20ppm |
| Ubumuncu | 4.0~7.0 |
| Isomer | ≤0.50% |
| Ukungacoceki Okukodwa | ≤0.50% |
| Ukungcola ngokupheleleyo | ≤1.0% |
| Izinyibilikisi ezishiyekileyo | |
| IMethanol | ≤0.30% |
| Dichloromethane | ≤0.05% |
| Hexane | ≤0.02% |
| I-Ethyl Acetate | ≤0.50% |
| Umgangatho woVavanyo | Umgangatho woShishino |
| Ukusetyenziswa | API |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, Igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma kunye nokuhlaselwa zizinambuzane.
I-Shanghai Ruifu Chemical Co., Ltd. ngumenzi ohamba phambili kunye nomthengisi we-Bortezomib (CAS: 179324-69-7) kunye nomgangatho ophezulu, i-API.
I-Bortezomib, ethengiswa phantsi kwegama le-brand ye-Velcade phakathi kwabanye, iyeza elichasene nomhlaza elisetyenziselwa ukunyanga i-myeloma eninzi kunye ne-mantle cell lymphoma.I-Bortezomib yavunywa ukusetyenziswa kwezonyango e-United States kwi-2003 nakwi-European Union kwi-2004. Ikwi-World Health Organization's List of Essential Medicines.I-Bortezomib yi-proteasome inhibitor yokuqala ukuba ivunywe yi-US FDA ye-myeloma eninzi, umhlaza wegazi.I-reversible inhibitor ye-26S proteasome-i-barrel-shaped multiprotein particle efumaneka kwi-nucleus kunye ne-cytosol yazo zonke iiseli ze-eukaryotic.I-Bortezomib ikhethiweyo kwaye inamandla i-26S proteasome inhibitor, i-boronic acid dipeptide derivative.Izifundo zeseli zomhlaza we-pancreatic yomntu zibonisa i-Bortezomib ukuvimbela i-PKR-efana ne-endoplasmic reticulum (ER) kinase kunye nokuphucula uxinzelelo lwe-ER, olukhokelela kwi-apoptosis.
